StageZero Life Sciences Ltd
TORONTO, ON / ACCESSWIRE / March 14, 2022 / StageZero Life Sciences, Ltd. (TSX:SZLS) (OTCQB:SZLSF) ("StageZero" or the "Company"), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, announces that the Care Oncology Clinic service and COC Protocol is now available to patients living in Europe. This builds on the availability of the service and program in the UK, the US and Canada.
Care Oncology Clinic provides high quality outpatient treatment in an independent setting with experienced UK and European specialists. The Clinic offers adjunctive treatments that may complement or enhance standard-of-care cancer management. Its patented COC Protocol incorporates a multifaceted approach, supported by peer-reviewed scientific studies, which highlight the potential of certain treatments to target the specific energy requirements of cancer cells, impacting their ability to grow and multiply. The addition of non-cytotoxic agents with well-established safety profiles seeks to impede the prospects of cancer cell survival, especially in a hostile environment, such as during chemotherapy, radiotherapy, immunotherapy and hormone therapy.
Care is personalized for individual needs and patients receive regular monitoring and support. The service is available both in person at premises in Harley Street, London, UK, and remotely via telemedicine.
"Europe, with a population of approximately 750 million, and a healthcare focus that matches our early detection and management of cancer approach, is a natural extension to our successful Clinics in the UK. We are pleased to continue expanding the availability of our programs geographically and this builds upon our corporate long term growth initiatives of broadening, deepening and expanding our offerings" said James Howard-Tripp, Chairman and CEO of StageZero.
About StageZero Life Sciences, Ltd.
StageZero Life Sciences, Ltd. is a vertically integrated healthcare company dedicated to improving the early detection and management of cancer and other chronic diseases through next-generation diagnostics and unique telehealth programs that provide clinical interventions to assist patients who currently have cancer (COC Protocol) as well as help patients reduce the risk of developing late-stage disease (AVRT™).
The Company's next generation test, Aristotle®, is the first ever mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle® uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. This underlying technology has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.
The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Developed by scientists and oncologists, the COC Protocol is intended for adjunctive administration alongside standard-of-care cancer therapy. It is an individualized therapeutic approach which seeks to simultaneously target multiple metabolic cancer pathways. The aim is to restrict cancer cell energy supply and use, which may make it more difficult overall for cancer cells to survive, grow and adapt to changing conditions in the body. As a result, such cells can potentially become more vulnerable to attack from cell-killing therapies such as radiotherapy and chemotherapy. Its patented COC Protocol incorporates a multifaceted approach, supported by peer-reviewed scientific studies, which highlight the potential of certain treatments to target the specific energy requirements of cancer cells, impacting their ability to grow and multiply.
AVRT is a Physician-Led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Our program includes: a comprehensive online health evaluation; blood tests to measure markers of inflammation and metabolism; an in-depth initial physician consultation; regular physician follow-up appointments and interval screening.
Aristotle®, as well as additional cancer diagnostics (ColonSentry®, BreastSentry™, and the Prostate Health Index) are processed at the Company's clinical laboratory, StageZero Life Sciences, Inc., a CAP accredited and CLIA certified high-complexity reference laboratory in Richmond, Virginia. In addition, the Company is also leveraging its specialty in polymerase chain reaction (PCR) testing to provide COVID-19 PCR testing (swab and saliva) and Antibody Testing (blood analysis).
StageZero Life Sciences trades on the Toronto Stock exchange under the symbol SZLS and on the OTCQB under the symbol SZLSF.
Forward-Looking Statements
This press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
For further information please contact:
Investor Relations
Rebecca Greco
1-855-420-7140 ext. 1838
rgreco@stagezerols.com
SOURCE: StageZero Life Sciences
View source version on accesswire.com:
https://www.accesswire.com/692888/StageZero-Life-Sciences-Announces-Availability-of-COC-Protocol-in-Europe
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Air T Welcomes Creditor Support for Rex Acquisition11.11.2025 23:00:00 CET | Press release
MINNEAPOLIS, MINNESOTA / ACCESS Newswire / November 11, 2025 / Air T, Inc. (NASDAQ:AIRT) is pleased to announce that a majority of Rex's creditors-both in number and in value-have voted in favor of our bid to acquire Rex at the second meeting of creditors held on 11 November 2025. This strong endorsement reflects confidence in our vision for Rex and our commitment to regional aviation in Australia. We take our responsibilities under the proposed Deed of Company Arrangement seriously. We understand the Administrators intend to close the transaction by year-end, and we are working closely with all parties to ensure a smooth and timely completion. Air T is grateful for the support shown throughout this process and looks forward to finalizing the acquisition and beginning a new chapter for Rex and regional communities across Australia. NOTE REGARDING STAKEHOLDER QUESTIONS If you have questions related to this release or other Air T matters, please use our interactive Q&A capability, throug
MicroVision Announces Third Quarter 2025 Results11.11.2025 22:05:00 CET | Press release
REDMOND, WASHINGTON / ACCESS Newswire / November 11, 2025 / MicroVision, Inc. (NASDAQ:MVIS), a technology pioneer delivering advanced perception solutions in autonomy and mobility, today announced its third quarter 2025 results. Key Business and Operational Highlights Appointed 30-year industry veteran Glen DeVos as Chief Executive Officer, elevating automotive capabilities. Introduced next generation solid-state lidar sensor, MOVIA S, offering an energy-efficient and cost-effective short-range solution for a wide variety of automotive, industrial, and defense sector applications. Launched industry-disrupting Tri-Lidar Architecture solution, offering an alternative to the lidar industry's myopic focus on single sensor solutions. Executed agreement to acquire Scantinel Photonics, a German developer of long-range FMCW lidar, joining investment and strategic partners in advancing lidar-on-chip solution for commercial vehicle and passenger car markets. Established design office and testing
Climate Goals Threatened by Industrialised Animal Farming, Reveals Key International Study11.11.2025 15:20:00 CET | Press release
LONDON, UK / ACCESS Newswire / November 11, 2025 / A new study in Animals highlights that industrialized animal farming is one of the most powerful - yet persistently neglected - forces driving the climate and biodiversity crises. The analysis, "The Missing Target: Why Industrialized Animal Farming Must Be at the Core of the Climate Agenda," synthesizes evidence from 47 international studies and concludes that reducing livestock production and embracing plant-based food systems is essential for meeting global climate goals. Major Insights Across global research, livestock farming contributes an estimated 12-20% of all greenhouse gas emissions annually, with the most comprehensive studies yielding the highest figures. The most modern accounting methods, which include the impacts of deforestation, bottom trawling and cooling effects from certain atmospheric pollutants, reveal that 52% of present-day global warming is attributable to animal agriculture. Animal agriculture occupies over 80
Resin Solutions Announces Commencement of up to $100 Million Global HTPB Production Expansion Initiative11.11.2025 15:00:00 CET | Press release
EXTON, PA / ACCESS Newswire / November 11, 2025 / Resin Solutions, Exton, PA, a portfolio company of Pacific Avenue Capital Partners, announced a multi-phase production capacity expansion initiative for its hydroxyl-terminated polybutadiene ("HTPB") product line, Poly bd®. Resin Solutions has begun the initial expansion phase, which includes debottlenecking initiatives and major capital investments at the company's Channelview, Texas and Ravenna, Italy facilities, which would expand existing capacity to meet expected additional demand for critical U.S. National Security Programs. In addition, the Resin Solutions Board has commenced a scoping and feasibility assessment to support additional greenfield capacity expansion in the United States and Europe. The Board of Resin Solutions, with support from Pacific Avenue Capital Partners, has authorized investment of up to $100 million to ensure Resin Solutions remains able to serve growing customer demand for HTPB in its aerospace, defense, a
MicroVision Collaborates with Leading Photonics Ecosystem to Acquire FMCW Lidar Business10.11.2025 22:05:00 CET | Press release
REDMOND, WA / ACCESS Newswire / November 10, 2025 / MicroVision, Inc. (NASDAQ:MVIS), a technology pioneer delivering advanced perception solutions in autonomy and mobility, today announced that it had entered into an agreement to acquire the business and assets of Scantinel Photonics GmbH, a developer of 1550nm frequency-modulated continuous wave, or FMCW, lidar technology targeted for initial application in the commercial vehicle market. In connection with the acquisition, MicroVision is collaborating with certain funding and strategic partners to accelerate productization and commercial opportunities. Scantinel Photonic's core technology was developed with financial backing and key support from Zeiss Group, a German manufacturer of optical systems and optoelectronics; Scania, a Swedish commercial trucking OEM; and PhotonVentures, a deep tech venture capital firm purely focused on the key enabling technology of integrated photonics and a strategic partner of PhotonDelta, a Dutch distr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom